Learn About Tuberculosis Prevention Strategies

Understanding Tuberculosis and How It Spreads

Tuberculosis, commonly called TB, is an infection caused by bacteria called Mycobacterium tuberculosis. According to the World Health Organization, TB remains one of the top 10 causes of death worldwide, with approximately 10 million people developing TB disease each year. Understanding how TB spreads is the foundation for prevention efforts in communities and households.

TB primarily spreads through the air when a person with active TB disease in their lungs or throat coughs, sneezes, speaks, or sings. These tiny droplets containing bacteria can travel several feet and be inhaled by other people. Unlike some common misconceptions, TB does not spread through touching, sharing food or drinks, or shaking hands with an infected person. A person cannot catch TB from someone's clothing, bedding, or personal items.

There are two main types of TB infection: latent TB infection and TB disease. Latent TB infection occurs when the bacteria are in a person's body but not causing illness, and the person cannot spread TB to others. Approximately one-quarter of the world's population is believed to have latent TB infection. TB disease happens when the infection becomes active, causing symptoms like persistent cough, chest pain, and fever. People with TB disease can spread the infection to others, particularly if they have not yet started treatment or have not been treated for at least two weeks of appropriate medication.

Certain groups face higher risk of developing TB disease if exposed to the bacteria. These include people with weakened immune systems, those living in crowded conditions, individuals with diabetes or kidney disease, and people who misuse alcohol or drugs. Healthcare workers and those in close contact with TB patients also have increased exposure risk.

Practical Takeaway: Recognizing that TB spreads through airborne droplets—not through casual contact—helps people understand where prevention efforts should focus, particularly in enclosed spaces with poor ventilation where people spend extended time together.

Vaccination as a Prevention Tool

The Bacille Calmette-Guérin vaccine, known as BCG, has been used for TB prevention since the 1920s. BCG is the most widely used vaccine globally, with over 90% of children in most countries receiving this vaccine as part of standard childhood immunization schedules. The vaccine works by triggering the immune system to recognize and fight TB bacteria before exposure to the actual infection occurs.

BCG vaccination provides varying levels of protection depending on age and geographic location. Studies show that BCG vaccination prevents approximately 80% of severe tuberculosis cases in infants and young children, particularly preventing the most serious forms like TB meningitis and miliary TB. The vaccine is most effective when given shortly after birth, though protection levels can decrease over time. In some populations, BCG provides up to 80% protection, while in others the protection ranges from 0% to 60%, depending on factors like local disease prevalence and population genetics.

In countries with high TB burden, BCG remains a cornerstone of childhood vaccination programs. Many nations administer BCG as part of their routine newborn care in hospitals. However, vaccination strategies differ by country based on TB epidemiology. Some low-incidence countries have discontinued routine BCG vaccination, instead using targeted testing and preventive therapy for high-risk individuals. The United States, for example, does not include BCG in its routine vaccination schedule for the general population, though it may be offered to specific high-risk groups.

It is important to note that BCG vaccination does not provide guaranteed protection for all people, particularly in areas with drug-resistant TB strains. Additionally, BCG-vaccinated individuals may show a positive reaction to certain TB skin tests, which healthcare providers consider when interpreting test results. Newer TB vaccines are currently in development and clinical trials, with some showing promise in providing better protection, particularly in adults and against drug-resistant TB.

Practical Takeaway: Understanding that BCG vaccination is one component of TB prevention—and that its effectiveness varies—helps individuals recognize why vaccination alone cannot prevent all TB cases and why other prevention strategies remain necessary.

Testing and Early Detection Methods

Detecting TB infection early is crucial for preventing disease progression and stopping transmission to others. Two main methods are used to identify TB infection: the tuberculin skin test (TST), also called the Mantoux test, and TB blood tests. Both tests can indicate TB infection, though they cannot distinguish between latent TB infection and TB disease. Additional testing, such as chest X-rays or sputum tests, is necessary to confirm active TB disease.

The tuberculin skin test involves injecting a small amount of tuberculin purified protein derivative (PPD) under the skin. A healthcare provider examines the injection site after 48 to 72 hours to measure any raised, hard area (induration) that develops. The size of this reaction helps determine whether TB infection is present. However, reactions can be influenced by previous BCG vaccination, which is why interpretation requires professional assessment. False positives and false negatives can occur, though false negatives are more common in people with weakened immune systems, such as those with HIV/AIDS.

TB blood tests, also called interferon-gamma release assays (IGRAs), measure immune system response to TB antigens. These tests include the QuantiFERON Gold test and the T-SPOT test. Blood tests offer several advantages: they require only one office visit, they are not affected by previous BCG vaccination, and they may be more specific than skin tests in certain populations. These tests also provide results within 24 hours in many cases. Studies indicate that blood tests have sensitivity rates ranging from 85% to 99% in people with active TB disease and specificity rates of 95% to 99%.

People who should consider testing include those with prolonged close contact with TB patients, healthcare workers, people with HIV, individuals with medical conditions that weaken immunity, people living in congregate settings like shelters or prisons, and those from countries with high TB prevalence. Regular testing may be recommended for people in these groups, particularly those in high-risk occupations or living situations.

Practical Takeaway: Learning about available testing methods allows individuals and healthcare providers to choose the most appropriate test based on personal circumstances, previous vaccinations, and access to follow-up care, ensuring timely detection of TB infection.

Preventive Therapy for Latent TB Infection

Preventive therapy represents one of the most effective ways to prevent TB disease in people with latent TB infection. When someone has latent TB infection but has not yet developed disease symptoms, taking preventive medications significantly reduces the risk of progression to active TB disease. The World Health Organization recommends preventive therapy for people with latent TB infection, particularly those at highest risk of developing TB disease.

Several preventive therapy regimens exist, and healthcare providers select specific options based on individual circumstances. The most common regimen is isoniazid taken for 6 to 9 months. Studies demonstrate that isoniazid preventive therapy reduces the risk of TB disease development by approximately 60% to 90%, depending on adherence and individual factors. Shorter regimens have been developed for certain populations. For example, rifapentine combined with isoniazid, taken for 3 months, offers convenience of fewer pills and shorter duration. A 4-month rifampin regimen is another option for people who cannot tolerate isoniazid.

Preventive therapy is particularly important for certain groups. People living with HIV who have latent TB infection face a 20 to 37% annual risk of developing TB disease if not treated—substantially higher than the general population. Starting preventive therapy for people with HIV and latent TB infection can prevent this progression. Individuals with diabetes, chronic kidney disease, immunosuppressive conditions, and those taking medications that weaken the immune system also benefit significantly from preventive therapy.

Taking preventive medication requires consistency and completion of the full prescribed course. Missing doses or stopping treatment early reduces effectiveness and may allow bacteria to multiply. Healthcare providers often work with patients through the course of treatment, monitoring for side effects—though most people tolerate these medications well—and providing reminders about the importance of completing the regimen. Some clinics offer directly observed therapy, where a healthcare worker watches the patient take their medication, which improves completion rates.

Practical Takeaway: Understanding that preventive medications can dramatically reduce TB disease risk in people with latent infection emphasizes the importance of completing testing and engaging with treatment recommendations, even when feeling healthy.

Environmental Controls and Public Health Measures

Environmental controls play an important role in preventing